AARD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aardvark Therapeutics Inc (AARD) is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant uncertainty due to paused clinical trials, safety concerns, and negative sentiment from analysts and the market. While the company has sufficient cash to fund operations into 2Q27, the regulatory and clinical risks outweigh the potential rewards in the near term.
The technical indicators suggest a bearish trend. The moving averages are aligned bearishly (SMA_200 > SMA_20 > SMA_5), and RSI is neutral at 37.819. The MACD histogram is positive but contracting, indicating weakening momentum. The stock is trading below its pivot level of 3.875, with key support at 3.478 and resistance at 4.273.
Lower doses of ARD-101 may mitigate risks and support a redesigned Phase 3 program. Potential unblinded Phase 3 PWS data and FDA feedback in 2Q26 could provide clarity.
The voluntary pause of the Phase 3 HERO trial due to cardiac safety concerns has raised significant uncertainty. Analysts have downgraded the stock, and price targets have been drastically reduced. Legal investigations and communication concerns with the FDA further compound the risks.
In 2025/Q4, the company reported zero revenue, with a net income of -$17.598M (improved by 100.46% YoY). EPS increased to -0.81, up 97.56% YoY. However, the lack of revenue and consistent losses highlight financial challenges.
Analyst sentiment is predominantly negative. Multiple firms have downgraded the stock and significantly lowered price targets due to safety concerns and trial pauses. The highest price target is now $45, down from $50, while the lowest is $6, down from $18. Analysts emphasize uncertainty and regulatory risks in the near term.
